Mabwell's LILRB4/CD3 Bispecific Antibody Clears NMPA for Clinical Trials in Hematologic Malignancies
Event summary
- Mabwell's LILRB4/CD3-targeting TCE bispecific antibody 6MW5311 received IND clearance from China's NMPA for clinical trials in AML, CMML, and MM.
- 6MW5311 is the first globally approved LILRB4/CD3 targeting TCE drug candidate, following prior FDA clearance.
- The molecule features a unique '2+1' asymmetric structure designed to enhance safety and anti-tumor efficacy.
- Preclinical studies showed potent cytotoxic activity and complete tumor clearance in high-expression AML models.
The big picture
Mabwell's NMPA clearance for 6MW5311 positions it at the forefront of TCE-based therapies targeting hematologic malignancies, an area with significant unmet medical needs. The approval underscores the growing importance of bispecific antibodies in oncology and highlights Mabwell's ability to navigate dual regulatory pathways in China and the U.S.
What we're watching
- Clinical Trial Progress
- The pace at which 6MW5311 advances through clinical trials will determine its commercial potential in AML, CMML, and MM.
- Competitive Positioning
- Whether Mabwell can establish 6MW5311 as a leading TCE therapy in indications currently dominated by chemotherapy and targeted therapies.
- Regulatory Strategy
- How Mabwell balances simultaneous development under both NMPA and FDA approval pathways to accelerate global market entry.
Related topics